For how we live.
A Toronto cohort reports that an eight-day antiviral protocol prevented or cleared hepatitis C in all 116 recipients of organs from infected donors, with survival matching recipients of uninfected organs.
RESOLVE randomised 880 treatment-naive, non-cirrhotic patients to a shorter sofosbuvir–velpatasvir course; cure rates were non-inferior to the 12-week standard, with implications for the cost of elimination programmes.
A Cochrane review of 18 trials and an NIH-funded randomised trial both failed to show that milk thistle improves liver disease. Product quality is also inconsistent, with some pills contaminated or mislabelled.
ECDC data show near-zero hepatitis B in under-fives and vertical transmission below 2%, alongside five million chronic infections and only seven countries meeting the harm-reduction benchmark.
Two 2026 reviews describe the same handover: as the virus recedes, obesity-driven fatty liver disease is moving into the space it occupied — in a population where roughly 40% of screened adults met obesity criteria.